Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

Dow Jones

02-05

0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

February 05, 2025 03:47 ET (08:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2509247456"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509247456\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2509247456?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509247456","market":"hk","top_or_hot":-1,"title":"Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 03:47 ET (08:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-05 16:47</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 03:47 ET (08:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"諾和諾德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2509247456","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509247456","pubTimestamp":1738745220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德强劲的销售前景令人放心——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0847 GMT - Novo Nordisk's 2025 outlook is reassuring, says Sheena Berry at Quilter Cheviot. The Danish pharmaceutical company expects a robust 16%-24% sales growth for the year, Berry says. Fourth-quarter sales rose 30%, outpacing expectations, although this was partly driven by insulin rebate adjustments, she notes. The performance of key growth drivers, Ozempic and Wegovy, remains strong, with Ozempic meeting expectations and Wegovy slightly underperforming. Novo Nordisk is set to initiate a new CagriSema Phase 3 trial in 2025 and plans to file with regulators in the first quarter of 2026, a slight delay to ensure a secure supply chain. Shares trade 4.5% higher at 619 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2025 03:47 ET (08:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}